Related Experiment Videos
Thymic development in human CD4 transgenic mice. Positive selection occurs after commitment to the CD8 lineage
R K Paterson1, L C Burkly, D K Kurahara
1Department of Pediatrics, National Jewish Center for Immunology and Respiratory Medicine, Denver, CO 80206.
Journal of Immunology (Baltimore, Md. : 1950)
|October 15, 1994
Summary
Positive selection of developing T cells occurs late in thymocyte differentiation, after commitment to the CD8 lineage. This study used transgenic mice to demonstrate that CD8+ T cell development depends on T cell receptor recognition of major histocompatibility complex (MHC) molecules.
Area of Science:
- Immunology
- Cell Biology
Background:
- T cell development involves positive selection based on T cell receptor (TCR) recognition of major histocompatibility complex (MHC) molecules.
- CD4 and CD8 co-receptors guide T cell maturation, with thymocytes initially co-expressing both before committing to a single lineage.
- The precise timing of positive selection during thymocyte differentiation remains debated.
Purpose of the Study:
- To investigate the stage at which positive selection occurs during T cell development.
- To determine if positive selection precedes or follows co-receptor lineage commitment.
Main Methods:
- Development of transgenic (TG) mice expressing human CD4 (huCD4).
- Breeding huCD4 TG mice with mice lacking class I MHC (class I-) to study CD8+ T cell differentiation.
- Analysis of thymocyte maturation and co-receptor expression in genetically modified mice.
Main Results:
- In the absence of huCD4, class I- mice failed to produce CD8+ T cells.
- Expression of huCD4 enabled the development of CD8+ T cells in class I- mice, suggesting selection of cells already committed to the CD8 lineage.
- Increased CD8+ T cells were observed in both the thymus and periphery of huCD4 TG x class I- mice.
Conclusions:
- Positive selection of T cells occurs at a late stage of thymocyte differentiation.
- This selection event takes place after lineage commitment to the CD8+ phenotype.